• MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil

    FOSTER CITY, Calif. and SHANGHAI, China – September 21, 2018 – MicuRx Pharmaceuticals, Inc. today announced the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track status by the U.S. Food and Drug Administration (FDA) for contezolid (MRX-I) and its prodrug contezolid acefosamil (MRX-4) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

    QIDP designation is granted under the U.S. Generating Antibiotic Incentive Now (GAIN) Act, which is part of the FDA Safety and Innovation Act of 2012 (FDASIA). The Act provides incentives for the development of antimicrobials active against priority bacterial pathogens, and includes Fast Track designation for review and five years of market exclusivity added to any non-patent exclusivity.

    “MicuRx is proud to have received QIDP and Fast Track designation for our oxazolidinone agents, contezolid and the prodrug contezolid acefosamil,” commented Mike Gordeev, Ph.D., MicuRx’s Chief Scientific Officer. “We believe that this FDA designation affirms the need for new drugs effective against the priority pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).”

    Contezolid and contezolid acefosamil are next-generation oxazolidinone agents with notably reduced hematologic toxicity, while maintaining the excellent therapeutic efficacy of the class. Contezolid and contezolid acefosamil are active against multidrug-resistant, Gram-positive organisms, including MRSA and VRE, which are categorized as a high threat by the World Health Organization.

    “Despite recent antibiotic launches, unmet needs still exist for an oral anti-MRSA agent with a safety profile appropriate for extended treatment, especially in the outpatient setting,” stated Barry Hafkin, M.D., MicuRx’s Chief Medical Officer. “We believe that our contezolid portfolio offers a unique profile with excellent clinical safety and efficacy results to date, with the flexibility of intravenous and oral formulations. Transitioning patients with serious infections from the hospital to oral outpatient treatment as soon as possible is a more convenient and more cost effective treatment compared to continued hospitalization or outpatient IV treatment.“

    About Methicillin-Resistant Staphylococcus Aureus (MRSA)
    MRSA is the world’s most common drug-resistant human bacterial pathogen, responsible for millions of infections in the skin, bone, lung, and bloodstream, and results in tens of thousands of deaths worldwide annually. While several antibiotics with activity against MRSA are marketed, very few oral agents against serious infections are available. New oral treatment options with an improved safety profile are needed for the outpatient MRSA therapy, as well as for the preferred transition from intravenous to oral therapy providing maximum convenience to patients and minimizing hospitalization time and cost.
    About MicuRx Pharmaceuticals, Inc.

    MicuRx is a privately-held, late-stage biopharmaceutical company whose mission is to discover and develop effective antibiotics with improved safety profiles to improve the treatment of resistant bacterial infections. The lead compounds, contezolid (MRX-I) and contezolid acefosamil (MRX-4), next-generation oxazolidinones targeting methicillin-resistant S. aureus (MRSA), were structure-designed to reduce hematological adverse events of this antibiotic class. In 2015, MicuRx completed two independent Phase 2 studies in the US and China for oral contezolid, and is currently nearing completion of the Phase 3 program in China for the treatment of complicated skin and soft tissue infections (cSSTI). The U.S. Phase 2 study of oral and IV contezolid acefosamil in ABSSSI is scheduled to begin in 2H2018. The company has research and development facilities outside San Francisco, CA, in the United States, and in Shanghai, China. MicuRx has raised a total of $107 million through leading venture capital firms, including Morningside Ventures, BVCF, GP Healthcare Capital, GP TMT Capital, 3E Bioventures Capital, and Delian Capital. Visit www.micurx.com for more information.